汇丰研究报告指，泰格医药(03347.HK) 公布去年收入及经常性净利润预测；以中间值计算，分别按年升8.6%及按年跌52%。新增订单额为95亿至105亿元人民币，以中间值计算即按年增长18.7%。期内收入及新增订单分别胜该行预期7%及3%，而经常性净利润则较预期低10%。该行将2026至2027年收入预测上调7%，但下调同期经常性净利润预测1%至3%；维持“买入”评级，将泰格医药H股目标价由59...
Source Link汇丰研究报告指，泰格医药(03347.HK) 公布去年收入及经常性净利润预测；以中间值计算，分别按年升8.6%及按年跌52%。新增订单额为95亿至105亿元人民币，以中间值计算即按年增长18.7%。期内收入及新增订单分别胜该行预期7%及3%，而经常性净利润则较预期低10%。该行将2026至2027年收入预测上调7%，但下调同期经常性净利润预测1%至3%；维持“买入”评级，将泰格医药H股目标价由59...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.